What Is Recent in Pancreatic Cancer Immunotherapy
TL;DR: This paper analyzes recent preclinical and clinical efforts towards immunotherapy of pancreatic cancer, including passive and active immunotherapy approaches, designed to target pancreatic-cancer-associated antigens and to elicit an antitumor response in vivo.
read more
Abstract: Pancreatic cancer (PC) represents an unresolved therapeutic challenge, due to the poor prognosis and the reduced response to currently available treatments. Pancreatic cancer is the most lethal type of digestive cancers, with a median survival of 4–6 months. Only a small proportion of PC patients is curative by surgical resection, whilst standard chemotherapy for patients in advanced disease generates only modest effects with considerable toxic damages. Thus, new therapeutic approaches, specially specific treatments such as immunotherapy, are needed. In this paper we analyze recent preclinical and clinical efforts towards immunotherapy of pancreatic cancer, including passive and active immunotherapy approaches, designed to target pancreatic-cancer-associated antigens and to elicit an antitumor response in vivo.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer
Lei Miao,Jingjing Li,Qi Liu,Richard Feng,Manisit Das,C. Michael Lin,Tyler J. Goodwin,Oleksandra Dorosheva,Rihe Liu,Leaf Huang +9 more
TL;DR: The trap therapy significantly modified the immunosuppressive TME to allow the host immune system to kill the tumor cells, and can be an effective therapy in clinical settings.
124
Gastric cancer and the epoch of immunotherapy approaches.
TL;DR: A panoramic view of the different immune-based strategies used for gastric cancer treatment and the results obtained in the most significant clinical trials is provided.
88
Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy
TL;DR: The immune suppressive mechanisms of pancreatic cancer are described and recent preclinical and clinical efforts toward PC immunotherapy are discussed, including passive approaches, such as the use of antibodies and active strategies (vaccination), with a special mention of most recent treatment with CRS-207 and GVAX.
85
New targeted therapies in pancreatic cancer
TL;DR: This review summarizes the new leading targeted therapies in pancreatic cancers, focusing on passive and specific immunotherapies, and mainly therapies targeting against kinases.
49
Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma
Elena Niccolai,Paola Cappello,Antonio Taddei,Federica Ricci,Mario Milco D'Elios,Marisa Benagiano,Paolo Bechi,Lapo Bencini,Maria Novella Ringressi,Andrea Coratti,Fabio Cianchi,Lisa Bonello,Paola Francia di Celle,Domenico Prisco,Francesco Novelli,Amedeo Amedei +15 more
TL;DR: Comparing the T cell receptor repertoire of ENO1-specific peripheral and infiltrating tumor T cells from the same patient suggests that ENO 1-specific T cells, despite having a different functional profile, can recirculate from the tumor to the periphery.
References
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
H. A. Burris,Malcolm J. Moore,J. S. Andersen,M R Green,Mace L. Rothenberg,M R Modiano,M. C. Cripps,Russell K. Portenoy,A M Storniolo,P Tarassoff,R Nelson,F A Dorr,C. D. Stephens,D. D. Von Hoff +13 more
TL;DR: It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
6.1K
The dendritic cell system and its role in immunogenicity
TL;DR: Dendritic cells are specialized to mediate several physiologic components of immunogenicity such as the acquisition of antigens in tissues, the migration to lymphoid organs, and the identification and activation of antigen-specific T cells.
5K
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore,David Goldstein,John T. Hamm,Arie Figer,J. R. Hecht,Steven Gallinger,Heather J. Au,Pawel Murawa,David Walde,Robert A. Wolff,D. M. B. Campos,Robert Lim,Keyue Ding,Gary M. Clark,Theodora Voskoglou-Nomikos,Mieke Ptasynski,Wendy R. Parulekar +16 more
TL;DR: To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.
3.9K
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
Frank O. Nestle,Selma Alijagic,Michel Gilliet,Yuansheng Sun,Stephan Grabbe,Reinhard Dummer,Günter Burg,Dirk Schadendorf +7 more
TL;DR: Vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma and antigen-specific immunity was induced during DC vaccination.
3K
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.
Concepcion Almoguera,Darryl Shibata,Kathleen Forrester,John Martin,Norman Arnheim,Manuel Perucho +5 more
TL;DR: It is concluded that c-K-ras somatic mutational activation is a critical event in the oncogenesis of most, if not all, human cancers of the exocrine pancreas.
2.2K
Related Papers (5)
Daniel D. Von Hoff,Thomas J. Ervin,Francis P. Arena,E. Gabriela Chiorean,Jeffrey R. Infante,Malcolm J. Moore,Thomas E. Seay,Sergei Tjulandin,Wen Wee Ma,Mansoor N. Saleh,Marion Harris,Michele Reni,Scot Dowden,Daniel A. Laheru,Nathan Bahary,Ramesh K. Ramanathan,Josep Tabernero,Manuel Hidalgo,David Goldstein,Eric Van Cutsem,Xinyu Wei,Jose Iglesias,Markus F. Renschler +22 more
Thierry Conroy,Françoise Desseigne,Marc Ychou,Olivier Bouché,Rosine Guimbaud,Yves Becouarn,Antoine Adenis,Jean-Luc Raoul,Sophie Gourgou-Bourgade,Jaafar Bennouna,Jean-Baptiste Bachet,Faiza Khemissa-Akouz,Denis Péré-Vergé,Catherine Delbaldo,Eric Assenat,Bruno Chauffert,C. Montoto-Grillot,Michel Ducreux +17 more